SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : January Effect 2007
IWM 247.30+0.9%Nov 26 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Carl Worth who wrote (24)12/20/2006 6:05:42 AM
From: gcrispin  Read Replies (1) of 94
 
Sorry for sounding a little harsh. It's just that "pretty good results" implies good news. To be specific, I just was a little surprised by your statement below.

"considering that someone in an ambulance or remote location wouldn't have the choice of blood or polyheme, it would basically be polyheme or death"

With all due respect, I consider that a very unlikely scenario. All ambulances have saline solution, the current and far cheaper treatment of choice, and from the trial it appears that someone in dire straits will be better off with saline solution than Polyheme.

So where do they go from here? My guess is that NFLD will eventually be a dollar plus stock while the company spins and grins in an effort to reinvent itself. I take the comments of trial discrepancies as an attempt to mine the data so that another trial can be initiated and keep those paychecks rolling in. After all, they buried the data once before. CTIC anyone? That's what this will look like in a couple of years.

Just my two cents, but if there is a January effect with NFLD, I would consider it an opportunity to short.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext